Randall Stevens, MD

Centrexion Therapeutics Corp.
Rockport, MA, United States

Randall Stevens, MD is a rheumatologist with 30 years of practice at the Robert Wood Johnson Medical School and 33 years as a pharmaceutical development professional at CIBA-Geigy, F. Hoffmann LaRoche, Celgene and is currently the chief medical officer at Centrexion Therapeutics. Drug brought to market include rituximab, tocilizumab, Mircera, ibandronate and apremilast.

Presentation(s):

• 0323: A Randomized, Double-blind, Placebo-controlled, Repeat Injection, 52-Week Study to Evaluate the Efficacy and Safety of an Intra-articular Injection (IAI) of CNTX-4975-05 (CNTX) in Subjects with Chronic, Moderate-to-severe Osteoarthritis Knee Pain (MSOAKP) - Study 304

  Sunday, November 12, 2023
  9:00 AM – 11:00 AM PT

  Disclosure information not submitted.

• 0324: A Randomized, Double-blind, Placebo-controlled, Single Injection, 52-Week Study to Evaluate the Efficacy and Safety of an Intra-articular Injection (IAI) of CNTX-4975-05 (CNTX) in Subjects with Chronic, Moderate-to-severe Osteoarthritis Knee Pain (OAKP) - Study 301

  Sunday, November 12, 2023
  9:00 AM – 11:00 AM PT

  Disclosure information not submitted.

• 1977: Combined Datasets for CNTX-4975 Osteoarthritis Knee Pain (OAKP) Phase 3 Trials (OAKP 301 and 304) to Assess Overall Efficacy and Safety of an Intra-articular Injection (IAI) of CNTX-4975-05 (CNTX) in Subjects with Chronic, Moderate-to-severe Osteoarthritis Knee Pain (MSOAKP)

  Tuesday, November 14, 2023
  9:00 AM – 11:00 AM PT

  Disclosure information not submitted.